Recognizing this dichotomy has direct clinical implications, suggesting that anti-inflammatory and insulin-sensitizing therapies may be prioritized for the adipose-dysfunction phenotype, whereas antifibrotic and weight-reduction approaches may be more effective in obesity-driven disease [1]. This evidence concerns the gene INS and obesity disorder.